GreyB Spotlight

Arthrex’s research investment is growing at a rate that stands above all other signals in their commercial profile, marking R&D acceleration as their most defining characteristic. That growth runs alongside high research intensity and strong revenue performance. Meaningful FDA product clearances add regulatory progress, completing a commercial picture that is engaged across multiple dimensions. The patent portfolio behind that commercial momentum is compact, with citation activity from the field showing technical engagement.

Carlsmed reached public markets with a personalized surgical planning platform for spinal fusion. The company brought the aprevo system to clinical use and earned FDA Breakthrough Device designation, signaling recognition of clinical novelty. Thousands of patients have been treated through the platform. Surgeon adoption is accelerating, and the system received dedicated reimbursement support from CMS. Revenue is scaling rapidly with strong margins, and the company maintains substantial cash reserves after its IPO.

Cilag’s patents draw notable citation engagement across a large, fully active portfolio. That pattern signals that other innovators are treating their work as technically relevant when filing new patents. Their peak individual asset is one of the strongest in the portfolio, and patent claims are well-constructed across the broader base. R&D investment relative to their business scale is high, supporting a research-driven approach and continued IP output.

Covidien has built a portfolio defined by breadth and scale. Their IP spans the full range of technology domains in robotic surgery, with a large volume of active patents maintained and current. The portfolio’s strength rests on cumulative depth: total coverage across the field sustained through continued filing. Research investment continues relative to their business scale, and every patent is kept active and operational.

DePuy Synthes commits a high share of their business resources to research in robotic surgery, and the patents that investment generates have drawn formal challenge proceedings from competitors. Those challenges confirm that the market treats their IP as commercially significant. Their patents completed examination with few objections, reflecting inventions built on clear technical ground. That research commitment reflects a company treating robotic surgery as an active development priority.

Globus Medical brings both substantial patent depth and strong commercial momentum to robotic surgery. Their revenue growth stands as the defining signal of their business profile, pointing to a company that converts its IP position into financial growth. Active M&A adds technology capability alongside organic development. Their portfolio is consistent in quality, fully active, and built with meaningful family depth around core inventions.

Howmedica Osteonics has built a focused portfolio defined by strategic positioning. Their patents carry blocking references that can constrain how competitors innovate around related technologies, and that signal stands as the most defining dimension of their IP profile. Deep family structures extend protection around each core invention. Half of their patents reach the high-value threshold, and citations arrive at a meaningful pace. Their commercial performance shows consistent growth. Howmedica Osteonics operates as a wholly owned subsidiary of Stryker Corporation, filing its patents in its own name.

Intuitive Surgical combines large portfolio scale with deep family structures built by filing related patents around core inventions, reflecting a long-term protective strategy. That depth extends coverage across adjacent technology areas. Their commercial profile distributes strength across revenue growth, R&D investment, regulatory progress, and acquisition activity, with every dimension contributing meaningfully. The position rests on consistent performance across every commercial indicator.

IX Innovation’s patents stand out for the efficiency of their examination process. Their inventions moved through patent examination with minimal friction, a signal of well-defined inventions that examiners accepted without significant pushback. The portfolio spans the full range of technology domains in robotic surgery and is entirely active. R&D spending continues to grow, and blocking references within the portfolio point to competitive positioning in adjacent technology areas.

J&J’s surgical robotics IP spans two entities with complementary strengths. Verb Surgical drives portfolio depth with 154 patents, superior average quality, and 43% high-value concentration. Auris Health brings clinical validation through FDA clearances and defensive presence despite smaller portfolio. Combined 253-patent position reflects maximal R&D commitment (100% intensity) and exceptional innovation velocity. Strong prosecution standards and geographic breadth reinforce market penetration. Absence of external acquisitions signals internally-driven development discipline.

Karl Storz’s commercial profile is shaped above all else by acquisition activity, which stands as the most defining signal in their business profile. They have expanded their technology capability through strategic transactions, building inorganic growth alongside research investment that is both meaningful and growing. Their patent portfolio is focused and fully active, covering the full range of technology domains in robotic surgery.

Kawasaki Heavy Industries brings a portfolio of moderate scale to robotic surgery, with well-constructed patent claims at its core. The claim quality across their portfolio is strong, reflecting inventions that have been carefully scoped. Commercial engagement extends beyond the patent position itself, with acquisition activity and revenue growth marking a company with active market presence.

The commercial story is KB Medical’s most distinguishing signal: revenue growth stands above all other dimensions of their business profile. Their IP consists of a compact portfolio with deep family structures around each core invention, building layered protection from a small base. Research investment at a meaningful share of revenue supports continued development.

Mako Surgical’s portfolio is shaped by the quality of individual inventions. Their patents carry well-constructed claims across the full range of technology domains in robotic surgery, with related follow-on filings that deepen protection around core assets. Their strongest single patent represents a notable peak within the portfolio. Revenue and R&D spending both show consistent growth, reflecting a business building on a quality-first foundation. Mako Surgical is a wholly owned subsidiary of Stryker Corporation and files patents under the Mako Surgical name.

Mazor Robotics holds a portfolio where the strength of individual patent claims has drawn competitive attention. Rivals have challenged their IP through formal proceedings, a pattern consistent with patents that define technical boundaries with care. The inventions are well-scoped, and research investment at a meaningful share of revenue sustains the development behind that precision. Mazor Robotics is a wholly owned subsidiary of Medtronic plc and files these patents under its own corporate name.

Mobius Imaging has assembled a compact portfolio in robotic surgery where the strategic blocking value of individual patents stands out relative to the portfolio’s overall scale. Their patents are positioned to constrain how competitors innovate in adjacent technology areas, with geographic coverage extending across multiple markets. Moderate revenue growth shows commercial traction alongside the IP position. Mobius Imaging is a wholly owned subsidiary of Stryker Corporation and files patents under its own name.

Moon Surgical builds with precision. A focused portfolio, strong per-patent quality, deep family structures around each core invention, and long enforceable life define their IP profile. The portfolio spans the full range of technology domains in robotic surgery, with every patent fully active. The field is engaging with their work through citations that arrive quickly after grant, drawing early attention. Active M&A reflects rapid technology expansion.

NuVasive generates strong commercial momentum from a compact patent base, with revenue growth as the single strongest signal in their business profile. Their IP is built with deliberate depth, concentrating protection around a focused set of inventions with a meaningful share reaching the high-value threshold. Research investment reinforces that foundation, sustaining development alongside the commercial performance.

Orthosoft connects its robotic surgery IP to market-facing output through FDA product clearances, demonstrating that development activity reaches the regulatory stage. Their portfolio sits at meaningful scale, backed by consistent research investment. Commercial engagement shows in steady revenue growth alongside those regulatory and research activities, marking a company with an active operational presence in the field. Orthosoft is a wholly owned subsidiary of Zimmer Biomet and files its patents under the Orthosoft name.

Philips files its robotic surgery patents with a deliberate international reach, with well-constructed claims extending protection across multiple markets. A high rate of FDA product clearances connects that IP coverage to actual market output. Strong research investment sits behind both, and targeted acquisition activity adds capability to a commercial profile anchored by regulatory momentum and geographic spread.

Smith & Nephew has built a fully active portfolio where family structures run deep relative to the overall portfolio size, reflecting a strategy of filing related patents around a focused set of core inventions. Their IP spans the full range of technology domains in robotic surgery. On the commercial side, regulatory output and acquisition activity are the two defining signals, with both contributing meaningfully to their business profile.

Stryker moves innovation through regulatory approval and into the market at a notable pace. FDA clearances define their commercial profile more than any other signal, showing a company that turns product development into market-ready output. Active M&A adds technology capability alongside that output. Their patent portfolio spans a wide range of technology domains, with every asset fully active and built on well-constructed inventions.

THINK Surgical’s commercial profile in robotic surgery engages across three dimensions: revenue growth, regulatory clearances, and acquisition activity all show positive movement. Each dimension contributes to a picture of a company building commercial presence from multiple angles. Their IP supports that trajectory through a compact portfolio where a meaningful share of patents reaches the high-value tier, backed by solid family depth around each core invention.

Trinity Capital has built a strong portfolio with a wide international footprint, filing across multiple markets in robotic surgery. Their IP spans the full range of technology domains within the field. The defining signal of their business profile is revenue growth, pointing to a company converting that market presence into financial momentum. Geographic reach and commercial performance align in the same direction.

University of Nebraska has built a compact portfolio where each core invention is surrounded by deep family coverage, creating a layered structure from a small base. Nearly half the patents reach the high-value threshold, backed by well-constructed claims. The inventions are tightly scoped, with applications that moved through examination without significant revision. Geographic filings extend across multiple international markets, signaling commercial relevance across borders.

Verily Life Sciences holds patents that play a dual role in robotic surgery: their inventions are referenced by other innovators at a high rate while also carrying blocking signals that can constrain how competitors develop in adjacent areas. Long enforceable life reinforces that position. R&D investment is both high relative to their business scale and growing, placing research at the center of how they build competitive capability.

Virtual Incision’s patents have attracted commercial transactions from third parties, a signal that the market has independently confirmed their value. The underlying IP is built on tightly drawn claims extending protection across multiple international markets, with a high proportion of the portfolio reaching the high-value tier. That combination of international reach and market validation gives the portfolio a credible commercial foundation.

Warsaw Orthopedic holds a portfolio of inventions with meaningful enforceable life remaining, each backed by well-constructed claims that define protection with precision. Research commitment relative to their business scale is meaningful, connecting a focused IP position to ongoing development activity. The combination of strong claims and remaining term creates a portfolio built to contribute commercially over time. Warsaw Orthopedic is a wholly owned subsidiary of Medtronic plc and files these patents under its own corporate name.